News & Media – Amarin Corporation plc

Amarin is a global pharmaceutical company committed to providing cost-effective cardiovascular care to high-risk adult cardiovascular patients. Find out more.

Committed to reducing the cardiovascular disease burden for patients and communities and to advancing the science of cardiovascular care around the world.

Amarin strives to ensure that our stakeholders have access to appropriate information about our financial growth.

Our latest news

Follow the links below for all the latest news from Amarin.

Date	Title	Format
July 29, 2026	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
July 15, 2026	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
June 30, 2026	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
May 27, 2026	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
April 29, 2026	Amarin Reports 2026 First Quarter Financial Results
April 15, 2026	Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
April 8, 2026	American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
March 18, 2026	Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
March 16, 2026	New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
March 2, 2026	Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

Media Contact form

If you’re a journalist or media professional, please feel free to get in touch with our media team by clicking the link below.

Disclaimer

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

You are about to leave the Amarincorp.com website

You have selected a link that will take you away from the amarincorp.com website. Amarin is not responsible for the content of the alternate website. Privacy and security policies of the alternate website may differ from those practiced by Amarin.

By clicking on the continue button below, you acknowledge the previous statement and will be taken to the linked site. If you want to remain at this site, select the cancel button. Thank you.